Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Accelerate Diagnostics | AXDX | Sep 19, 2024 | 1.47 | 0.00 |
Accenture A | ACN | Sep 19, 2024 | 335.24 | -0.28 |
Acco Brands | ACCO | Sep 19, 2024 | 5.46 | +1.49 |
Accolade | ACCD | Sep 19, 2024 | 4.19 | +0.24 |
Accuray | ARAY | Sep 19, 2024 | 1.90 | -0.52 |
Acelyrin | SLRN | Sep 19, 2024 | 5.30 | +15.22 |
Achieve Life Sciences | ACHV | Sep 19, 2024 | 4.56 | +3.64 |
Achilles Therapeutics ADR | ACHL | Sep 19, 2024 | 0.94 | +32.39 |
ACI Worldwide | ACIW | Sep 19, 2024 | 49.46 | +0.61 |
Aclarion | ACON | Sep 19, 2024 | 0.19 | +5.11 |
Aclaris Therapeutics | ACRS | Sep 19, 2024 | 1.21 | +3.42 |
ACM Research A | ACMR | Sep 19, 2024 | 17.48 | +5.72 |
Acme United | ACU | Sep 19, 2024 | 42.64 | +2.08 |
ACNB | ACNB | Sep 19, 2024 | 44.01 | +2.64 |
ACRES Commercial Realty | ACR | Sep 19, 2024 | 15.45 | +0.78 |
ACRES Commercial Realty C Pref | ACR-C | Sep 19, 2024 | 25.25 | +0.84 |
ACRES Commercial Realty D Pref | ACR-D | Sep 19, 2024 | 23.40 | +1.74 |
Acri Capital Acquisition Unit | ACACU | Sep 19, 2024 | 13.07 | +0.31 |
Acrivon Therapeutics | ACRV | Sep 19, 2024 | 7.59 | +0.40 |
Actelis Networks | ASNS | Sep 19, 2024 | 1.50 | -9.09 |
Actinium Pharmaceuticals | ATNM | Sep 19, 2024 | 1.88 | +5.62 |
Active Bear ETF | HDGE | Sep 19, 2024 | 18.84 | -2.28 |
Active U.S. Real Estate Powershares | PSR | Sep 19, 2024 | 99.06 | -0.04 |
Actuate Therapeutics | ACTU | Sep 19, 2024 | 8.19 | 0.00 |
Acuity Brands | AYI | Sep 19, 2024 | 271.99 | +1.52 |
Acumen Pharmaceuticals | ABOS | Sep 19, 2024 | 2.58 | +5.74 |
Acurx Pharmaceuticals | ACXP | Sep 19, 2024 | 2.04 | +3.55 |
Acushnet | GOLF | Sep 19, 2024 | 64.24 | +1.45 |
ACV Auctions A | ACVA | Sep 19, 2024 | 20.67 | +2.07 |
ACWI Ex-US Index MSCI Ishares | ACWX | Sep 19, 2024 | 56.14 | +1.98 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.